Article
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
The Journal of urology - 1 Sept 2008
Choueiri Toni K, Vaziri Susan A J, Jaeger Erich, Elson Paul, Wood Laura, Bhalla Ish Prasad, Small Eric J, Weinberg Vivian, Sein Nancy, Simko Jeff, Golshayan Ali-Reza, Sercia Linda, Zhou Ming, Waldman Frederic M, Rini Brian I, Bukowski Ronald M, Ganapathi Ram
Abstract excerpt
PURPOSE: The von Hippel-Lindau (VHL) gene is often inactivated (by mutation or promoter hypermethylation) in renal cell carcinoma but the relation to therapeutic outcome is unclear. MATERIALS AND METHODS: Patients with metastatic clear cell renal cell carcinoma with available baseline tumor samples who received vascular endothelial growth factor targeted therapy were included in analysis. Patient characteristics,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
